Administration of Angiotensin-Converting Enzyme Inhibitors and β-Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?

BACKGROUND. Adjuvant trastuzumab therapy improves the outcome of patients with early breast cancer (EBC) and overexpression of human epidermal growth factor receptor 2 (HER2). However, it is potentially cardiotoxic. This study aims to evaluate the relationship between the use of angiotensin-converti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Oliva, Stefano, Cioffi, Giovanni, Frattini, Silvia, Simoncini, Edda Lucia, Faggiano, Pompilio, Boccardi, Lidia, Pulignano, Giovanni, Fioretti, Agnese Maria, Giotta, Francesco, Lestuzzi, Chiara, Maurea, Nicola, Sabatini, Silvia, Tarantini, Luigi
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2012
Matèries:
Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399646/
https://ncbi.nlm.nih.gov/pubmed/22673631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0445
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars